MWN105

What is MWN105?

MWN105 is an investigational triple agonist from Shanghai Minwei Biotechnology, a majority-held subsidiary of Lepu Medical Technology, being developed for obesity and metabolic dysfunction-associated steatohepatitis. Its construct is unusual and worth stating precisely: a point-mutation-stabilised FGF21 variant is joined to a chimeric GLP-1/GIP dual-agonist peptide through an Fc fusion, producing a single molecule that engages the FGF21 receptor complex, the GIP receptor, and the GLP-1 receptor. So the GLP-1/GIP portion is a chimeric peptide while FGF21 is a full engineered protein domain, and the whole assembly is an Fc-fusion protein rather than a peptide in the strict sense. The design logic is a real gap in current obesity pharmacology. Incretin agonists reduce body weight extremely effectively but their direct effects on liver fibrosis are modest, while FGF21 analogs have produced the strongest signals in metabolic liver disease without delivering comparable weight loss. Combining them in one molecule targets both, and Minwei's own framing positions MWN105 against the approved FGF21 agonist on the grounds that its response rate for MASH resolution and fibrosis improvement remains suboptimal. There is also a distinctive clinical positioning: the Phase Ib trial enrolls specifically in semaglutide-intolerant overweight and obese adults, which is a real and growing population that current development programmes largely ignore. The evidence position needs to be stated bluntly, because it is thin. There is exactly one primary scientific disclosure of MWN105 in existence — a one-page late-breaking abstract presented by the sponsor at ADA 2025 (Song W., Diabetes 2025;74(Supplement_1):1968-LB). There are no peer-reviewed publications, no ClinicalTrials.gov registrations, and no human efficacy or safety data in the public domain. Every efficacy claim traces back to that single sponsor abstract. What elevates MWN105 above a bare trial registration is third-party commercial validation: on 31 October 2025 Lepu Medical disclosed that Minwei had licensed ex-Greater China rights to Sidera Bio ApS, a Novo Holdings-backed Danish biotech, for $35 million upfront plus near-term milestones, up to roughly $1.01 billion in cumulative development and sales milestones, a 9.99% equity stake in Sidera, and tiered royalties.

What MWN105 Is Investigated For

MWN105 should be read as an early-stage asset with a coherent mechanistic thesis and essentially no public human data. Anyone encountering it should calibrate accordingly. The thesis rests on a genuine division in metabolic drug development. GLP-1 and GLP-1/GIP agonists produce large, reliable weight loss and improve liver fat, but their effect on established fibrosis is limited. FGF21 analogs — efruxifermin, pegozafermin, and the approved resmetirom operating on a related axis — have produced the most convincing MASH resolution and fibrosis signals, but comparatively modest weight loss, and response rates that remain unsatisfying. A single molecule engaging all three receptors is a rational attempt to get both, and the design space is independently credible: Brunel and colleagues published a balanced FGF21/GLP-1R/GIPR triple agonist in Biochemistry in 2026 that near-normalised body weight in diet-induced-obese mice and outperformed GLP-1 benchmarks, and bifunctional FGF21/GLP-1 fusions have been characterised for MASH since at least 2023. Named competitors in the same space include HEC88473 (FGF21/GLP-1 dual, Phase 2) and DR10624 (FGF21R/GLP-1R/GCGR triple, Phase 2). Minwei's own preclinical package, per the ADA 2025 abstract, spans diet-induced-obese mice, B6-Alms1-del MASH mice, db/db mice, and MASH-diabetes non-human primates. In the NASH mouse model it reduced body weight, liver weight, and liver-to-body-weight ratio, lowered plasma ALT, AST, cholesterol and LDL-C, and reduced hepatic cholesterol and triglyceride. The headline non-human-primate result — 30 to 50% reduction in liver fat, roughly 2.5-point NAS improvement, and at least one-stage fibrosis improvement over ten weeks — is the most striking claim in the package, and it is also unreplicated, unpublished, and sponsor-reported. Four Chinese CDE trial registrations exist: a Phase I in healthy Chinese subjects (CTR20244754, first enrollment December 2024), the Phase Ib in semaglutide-intolerant overweight and obese adults (CTR20253330, n=40, weekly abdominal subcutaneous injection across 30/60/90/120 mg cohorts with titration over 12 weeks, started September 2025), the Phase II in non-diabetic overweight and obese adults with BMI at or above 30 or 27 to under 30 with a comorbidity (CTR20253336, primary endpoint percentage body-weight change at 24 weeks versus placebo, started September 2025), and a further Phase 1 (CTR20261331, started April 2026). None has reported. Note that some aggregator sites claim MWN105 has completed Phase II with positive results and entered Phase III enrollment — this appears to conflate MWN105 with MWN109, a sibling molecule that does have a registered Phase 3, and should not be repeated.

History & Discovery

MWN105 belongs to a specific moment in metabolic drug development: the point at which incretin agonists had clearly won the weight-loss argument and just as clearly not solved liver fibrosis. By the early 2020s semaglutide and tirzepatide had established that GLP-1 and GLP-1/GIP agonism could produce weight loss at magnitudes previously achievable only surgically, and that hepatic steatosis improved along the way. What did not follow was fibrosis regression. The incretin effect on liver histology appeared to run largely through weight loss rather than through direct action on the fibrotic process. Meanwhile a separate class was producing the opposite profile: FGF21 analogs including efruxifermin and pegozafermin generated the field's most convincing MASH resolution and fibrosis-improvement signals, with comparatively modest weight loss and response rates that left considerable room for improvement. Newsome and colleagues laid out the incretin-liver picture in the Journal of Hepatology in 2023. Combining the two mechanisms in one molecule became an active design problem. Ye and colleagues published a bifunctional FGF21/GLP-1 fusion protein for steatohepatitis in 2023. Chinese and Western groups pursued dual and triple constructs — HEC ChangJiang Pharma's HEC88473 as an FGF21/GLP-1 dual and Doer Biologics' DR10624 as an FGF21R/GLP-1R/GCGR triple both reached Phase 2 — and the concept received independent peer-reviewed validation when Brunel and colleagues reported a balanced FGF21/GLP-1R/GIPR triple agonist in Biochemistry in 2026 that near-normalised body weight in diet-induced-obese mice. Shanghai Minwei Biotechnology, a majority-held subsidiary of the Shenzhen-listed medical device and pharmaceutical company Lepu Medical Technology, built MWN105 by screening a point-mutation-stabilised FGF21 variant and fusing it, via an Fc scaffold, to a chimeric GLP-1/GIP dual-agonist peptide. The molecule entered first-in-human testing in healthy Chinese subjects under CDE registration CTR20244754, with first enrollment in December 2024 at Hangzhou First People's Hospital. Preclinical data were presented as a late-breaking abstract at the American Diabetes Association meeting in June 2025 — the only primary scientific disclosure of the molecule that exists — covering rodent obesity and MASH models plus a MASH-diabetes non-human-primate study with reported liver fat, NAS, and fibrosis improvements. Two trials opened in September 2025 and defined the clinical strategy. CTR20253330, a Phase Ib, enrolls 40 semaglutide-intolerant overweight and obese adults across escalating weekly subcutaneous doses — an unusual and commercially astute choice, since GLP-1 intolerance is common and almost entirely unaddressed by competing development programmes. CTR20253336, a Phase II, enrolls non-diabetic overweight and obese adults with a 24-week body-weight primary endpoint. A further Phase 1 (CTR20261331) began in April 2026. The validating event came on 31 October 2025, when Lepu Medical disclosed that Minwei had out-licensed MWN105 to Sidera Bio ApS, a Novo Holdings-backed Danish biotech that had raised a DKK 700 million Series A. Sidera took exclusive development and commercialisation rights outside Greater China — mainland China, Hong Kong, Macau, and Taiwan retained by Minwei — for $35 million upfront plus near-term milestones, up to roughly $1.01 billion in cumulative development and sales milestones, tiered royalties, and a 9.99% equity stake in Sidera for Minwei. For an asset with one conference abstract and no human results, a specialist buyer with Novo Holdings behind it paying real cash for global rights is the most informative signal available. That remains the position. MWN105 has a credible mechanism, credible commercial validation, four registered trials, and not one published human data point. It is worth tracking rather than worth conclusions.

How It Works

There are two broadly successful approaches to metabolic disease drugs right now, and each has a weakness. Gut-hormone drugs like semaglutide and tirzepatide produce large weight loss and clear fat out of the liver, but they do relatively little for liver scarring once it has set in. FGF21-based drugs are the opposite — they are the best tools available for reversing liver scarring and improving how the liver handles fat, but they do not cause much weight loss. MWN105 is one molecule built to do both jobs: an engineered version of FGF21 is stitched together with a hybrid gut-hormone peptide that activates both the GLP-1 and GIP receptors, all held on an antibody scaffold that keeps it in the bloodstream long enough for weekly dosing. One of its trials also does something unusual — it enrolls only people who could not tolerate semaglutide, a group most drug companies skip past.

MWN105 is a unimolecular triple agonist assembled by Fc fusion. Per the sponsor's ADA 2025 disclosure, a highly stable and active FGF21 variant carrying combined point mutations was screened and connected to a chimeric GLP-1 and GIP polypeptide through an Fc fusion. The resulting molecule therefore engages three distinct receptor systems. GLP-1 receptor activation drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and engages hypothalamic and brainstem circuits to suppress appetite. GIP receptor activation enhances insulin secretion under hyperglycaemic conditions, appears to improve adipose-tissue buffering of postprandial lipids, and contributes centrally to satiety through pathways partly distinct from GLP-1 — the dual-incretin combination validated by tirzepatide. FGF21 signals through a fundamentally different system: FGF receptors 1c, 2c, and 3c require beta-Klotho as an obligate co-receptor, which restricts FGF21 responsiveness to tissues expressing it — principally adipose tissue, liver, and pancreas. Downstream FRS2–ERK signalling drives increased energy expenditure, improved insulin sensitivity, adiponectin secretion from adipocytes, reduced hepatic de novo lipogenesis, and direct anti-fibrotic effects in the liver. The therapeutic rationale for combining these is a genuine asymmetry in the current landscape. Incretin agonists produce large weight loss and substantial hepatic fat reduction, but their effect on established fibrosis appears largely mediated through weight loss rather than direct anti-fibrotic action. FGF21 analogs — efruxifermin, pegozafermin — have produced the most convincing MASH resolution and fibrosis-improvement signals in the field but comparatively modest weight loss, and response rates that leave substantial unmet need. A single molecule engaging both axes could in principle deliver incretin-grade weight loss with FGF21-grade hepatic benefit. The design space has independent, peer-reviewed support that does not depend on Minwei's claims. Brunel and colleagues reported in Biochemistry in 2026 a high-potency balanced protein triple agonist at FGF21, GLP-1, and GIP receptors that normalised body weight in diet-induced-obese mice and outperformed GLP-1 benchmarks. Ye and colleagues characterised a bifunctional FGF21/GLP-1 fusion protein for non-alcoholic steatohepatitis in 2023. Newsome and colleagues reviewed the incretin-liver axis in the Journal of Hepatology in 2023, and a 2026 network meta-analysis updated the MASH pharmacotherapy landscape including emerging combination therapies. Minwei's own preclinical data, from the ADA 2025 abstract, spans diet-induced-obese mice, B6-Alms1-del MASH mice, db/db mice, and MASH-diabetes non-human primates. In the MASH mouse model MWN105 reduced body weight, liver weight, and liver-to-body-weight ratio; lowered plasma ALT, AST, total cholesterol and LDL-C; and reduced hepatic cholesterol and triglyceride content. In non-human primates over ten weeks the abstract reports 30 to 50% reduction in liver fat, approximately 2.5-point improvement in NAS, and at least one-stage fibrosis improvement. These are the sponsor's figures from an unreviewed abstract and have not been independently replicated or published in a peer-reviewed journal.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about MWN105:

• 01Any published human data at all — no efficacy, safety, tolerability, or pharmacokinetic results have been reported from any of the four registered Chinese trials, and there are no peer-reviewed publications on the molecule.
• 02Whether the tolerability hypothesis holds in semaglutide-intolerant patients. This is the most clinically interesting question the programme asks, and the Phase Ib is well designed to answer it, but it has not reported.
• 03Whether the non-human-primate liver results replicate in humans. A reported 30–50% liver fat reduction with roughly 2.5-point NAS improvement and at least one-stage fibrosis improvement over ten weeks would be remarkable if reproduced, and NHP MASH models have a mixed record of predicting human histology.
• 04The relative contribution of each receptor arm. With three mechanisms in one molecule, attributing any observed effect to FGF21 versus GLP-1 versus GIP requires dedicated pharmacology that has not been published.
• 05Whether triple agonism produces additive clinical benefit or merely additive tolerability burden — the standard risk when stacking mechanisms that each independently cause gastrointestinal adverse events.
• 06Bone turnover and blood pressure effects, both flagged in other FGF21-pathway programmes and neither characterised for MWN105.
• 07Immunogenicity of the Fc-fusion construct across chronic dosing.
• 08Competitive positioning against HEC88473 (FGF21/GLP-1 dual, Phase 2), DR10624 (FGF21R/GLP-1R/GCGR triple, Phase 2), and the established FGF21 analogs — no comparative data exist.
• 09Whether a US or European development programme will materialise under Sidera Bio, and on what timeline.

Forms & Administration

MWN105 is administered as a once-weekly subcutaneous injection into the abdomen in the Phase Ib trial, across 30, 60, 90, and 120 mg cohorts with titration over a 12-week treatment period. No formulation details, pharmacokinetic parameters, or dose-selection rationale have been published. There is no approved form, no commercial product, and no compounding pathway in any jurisdiction. The only legitimate access is enrollment in one of Shanghai Minwei's registered CDE trials in China. Because MWN105 is a recombinant Fc-fusion protein produced in mammalian cell culture rather than a synthesised peptide, it cannot be manufactured by the solid-phase chemistry that supplies research-chemical vendors — any product advertised under this name should be treated as implausible on that basis alone, quite apart from the absence of any human dosing data on which a protocol could be based.

Common Questions

Who MWN105 Is NOT For

Drug & Supplement Interactions

No drug-interaction data exist for MWN105, and none will until the clinical programme reports. Everything below is inferred from the three receptor systems the molecule engages. The incretin arms carry the interactions familiar from the GLP-1 and GLP-1/GIP classes. Combination with insulin or insulin secretagogues such as sulfonylureas and meglitinides raises hypoglycaemia risk and would be expected to require downward titration of the background agent. Delayed gastric emptying can alter absorption of orally administered drugs, which matters most for narrow-therapeutic-index agents including warfarin, levothyroxine, and oral hormonal contraceptives. Modest heart-rate elevation is seen across incretin therapies. The FGF21 arm adds considerations the incretin classes do not. FGF21-pathway agents have been associated in other development programmes with changes in bone turnover markers and, in some cases, blood pressure — so concomitant medications affecting bone metabolism or blood pressure would warrant attention if these signals prove real for MWN105. FGF21 also increases adiponectin and alters lipid handling, which could interact meaningfully with lipid-lowering therapy in ways that are difficult to predict directionally. Because MWN105 is a recombinant Fc-fusion protein rather than a small molecule or short peptide, immunogenicity is a distinct consideration: anti-drug antibodies could reduce exposure or, less commonly, cross-react with endogenous FGF21. This is monitored in trials rather than being an interaction in the conventional sense. There is no hepatic cytochrome P450 involvement, so classical CYP-mediated interactions are not anticipated.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions